Immunohistochemical differentiation of eosinophilic heart diseases using antibodies against eosinophil activation markers

Histopathology

Volumn 46, Issue 1, 2005, Pages 89-97

  Grabellus, F ^a,b   Mall, G ^c   Schnabel, P A ^d   Wieneke, H ^a   Pfeifer, U ^e   Kersting, C ^b   Schmitz, K J ^a   Wohlschlager J ^a   Sigusch, H H ^f   Bierhoff, E ^a   Kamler, M ^a   Scheld, H H ^b   Baba, H A ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c KLINIKUM DARMSTADT   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Endocarditis parietalis fibroplastica; Eosinophilia; Hypersensitivity myocarditis

Indexed keywords

CD69 ANTIGEN; CELL PROTEIN; DIURETIC AGENT; EOSINOPHIL CATIONIC PROTEIN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN EG1; PROTEIN EG2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENDOCARDITIS PARIETALIS FIBROPLASTICA; EOSINOPHIL; EXPLANT; FEMALE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; HYPERSENSITIVITY MYOCARDITIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; PRIORITY JOURNAL;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; DIAGNOSIS, DIFFERENTIAL; ENDOCARDITIS; EOSINOPHILS; FEMALE; HEART DISEASES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; MYOCARDITIS;

EID: 19944433158     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.01999.x     Document Type: Article

References (45)

1. Gould L, Reddy CV, Chua W, Swamy CR, Dorismond JC. Fibroplastic parietal endocarditis with eosinophilia. Angiology 1977; 28; 779-787.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83; 2759-2779.
3. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann. Intern. Med. 1982; 97; 78-92.
4. Parrillo JE, Borer JS, Henry WL, Wolff SM, Fauci AS. The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am. J. Med. 1979; 67; 572-582.
5. Olsen EG. Pathological aspects of endomyocardial flbrosis. Postgrad. Med. J. 1983; 59; 135-141.
6. Adler CP. [Obstructive-restrictive cardiomyopathy. On the clinical aspects and pathology of Loffler endocarditis]. Versicherungsmedizin 1989; 41; 151-154.
7. Kounis NG, Zavras GM, Soufras GD, Kitrou MP. Hypersensitivity myocarditis. Ann. Allergy 1989; 62; 71-74.
8. Gleich GJ. Mechanisms of eosinophil-associated inflammation. J. Allergy Clin. Immunol. 2000; 105; 651-663.
9. Spear GS. Eosinophilic explant carditis with eosinophilia: hypersensitivity to dobutamine infusion. J. Heart Lung Transplant. 1995; 14; 755-760.
10. Aggarwal A, Bergin P, Jessup P, Kaye D. Hypersensitivity myocarditis presenting as cardiogenic shock. J. Heart Lung Transplant. 2001; 20; 1241-1244.
11. Galiuto L, Enriquez-Sarano M, Reeder GS et al. Eosinophilic myocarditis manifesting as myocardial infarction: early diagnosis and successful treatment. Mayo Clin. Proc. 1997; 72; 603-610.
12. Uchino K, Fukuoka M, Kawasaki N et al. Acute eosinophilic myocarditis in a young woman. Jpn Circ. J. 2000; 64; 711-714.
13. Fenoglio JJ Jr, McAllister HA Jr, Mullick FG. Drug related myocarditis. I. Hypersensitivity myocarditis. Hum. Pathol. 1981; 12; 900-907.
14. Hawkins ET, Levine TB, Goss SJ, Moosvi A, Levine AB. Hypersensitivity myocarditis in the explanted hearts of transplant recipients. Reappraisal of pathologic criteria and their clinical implications. Pathol. Annu. 1995; 30; 287-304.
15. Rothenberg ME. Eosinophilia. N. Engl. J. Med. 1998; 338; 1592-1600.
16. Tai PC, Spry CJ, Peterson C, Venge P, Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 1984; 309; 182-184.
17. Sano K, Yamauchi K, Hoshi H, Honma M, Tamura G, Shirato K. CD44 expression on blood eosinophils is a novel marker of bronchial asthma. Int. Arch. Allergy Immunol. 1997; 114 (Suppl. 1); 67-71.
18. Hartnell A, Robinson DS, Kay AB, Wardlaw AJ. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993; 80; 281-286.
19. Hagendorff A, Hummelgen M, Omran H et al. [Loffler flbroblastic endocarditis in the thrombotic stages in isolated right ventricular tissue eosinophilia]. Z. Kardiol 1998; 87; 293-299.
20. Grabellus F, Hoffmeier A, Schmitz KJ et al. Resolved hypersensitivity myocarditis after ventricular circulatory assist. Ann. Thorac. Surg. 2003; 76; 2102-2104.
21. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol. Pathol. 1999; 52; 189-196.
22. Dallaire MJ, Ferland C, Lavigne S, Chakir J, Laviolette M. Migration through basement membrane modulates eosinophil expression of CD44. Clin. Exp. Allergy 2002; 32; 898-905.
23. Matsumoto K, Appiah-Pippim J, Schleimer RP, Bickel CA, Beck LA, Bochner BS. CD44 and CD69 represent different types of cell-surface activation markers for human eosinophils. Am. J. Respir. Cell Mol. Biol. 1998; 18; 860-866.
24. Katoh S, Taniguchi H, Matsubara Y et al. Overexpression of CD44 on alveolar eosinophils with high concentrations of soluble CD44 in bronchoalveolar lavage fluid in patients with eosinophilic pneumonia. Allergy 1999; 54; 1286-1292.
25. Bischof RJ, Meeusen EN. Cellular Kinetics of an allergic-type response in a sheep mammary gland model of inflammation. Clin. Exp. Allergy 2002; 32; 619-626.
26. Stevenson LM, Colditz IG, Lejambre LF. Expression of cell surface adhesion molecules by peripheral blood eosinophils during Trichostrongylus colubriformis infection in sheep. Immunol. Cell Biol. 2001; 79; 240-244.
27. Walsh GM. Eosinophil granule proteins and their role in disease. Curr. Opin. Hematol. 2001; 8; 28-33.
28. Durack DT, Ackerman SJ, Loegering DA, Gleich GJ. Purification of human eosinophil-derived neurotoxin. Proc. Natl Acad. Sci. USA 1981; 78; 5165-5169.
29. Peterson CG, Venge P. Purification and characterization of a new cationic protein-osinophil protein-X (EPX)-from granules of human eosinophils. Immunology 1983; 50; 19-26.
30. Olsson I, Venge P. Cationic proteins of human granulocytes. II. Separation of the cationic proteins of the granules of leukemic myeloid cells. Blood 1974; 44; 235-246.
31. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986; 321; 613-616.
32. Tai PC, Haves DJ, Clark JB, Spry CJ. Toxic effects of human eosinophil products on isolated rat heart cells in vitro. Biochem. J. 1982; 204; 75-80.
33. Spry CJ, Tai PC, Davies J. The cardiotoxicity of eosinophils. Postgrad. Med. J. 1983; 59; 147-153.
34. Noguchi H, Kephart GM, Colby TV, Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am. J. Pathol. 1992; 140; 521-528.
35. Pincus SH, Ramesh KS, Wyler DJ. Eosinophils stimulate fibroblast DNA synthesis. Blood 1987; 70; 572-574.
36. Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J. Clin. Invest. 1993; 91; 1721-1730.
37. Kishimoto C, Spry CJ, Tai PC, Tomioka N, Kawai C. The in vivo cardiotoxic effect of eosinophilic cationic protein in an animal preparation. Jpn Circ. J. 1986; 50; 1264-1267.
38. Spry CJ. Eosinophils in eosinophilic endomyocardial disease. Postgrad. Med. J. 1986; 62; 609-613.
39. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br. J. Dermatol. 2001; 145; 720-729.
40. Nakajima H, Loegering DA, Kita H, Kephart GM, Gleich GJ. Reactivity of monoclonal antibodies EG1 and EG2 with eosinophils and their granule proteins. J. Leukoc. Biol. 1999; 66; 447-454.
41. Jahnsen FL, Brandtzaeg P, Halstensen TS. Monoclonal antibody EG2 does not provide reliable immunohistochemical discrimination between resting and activated eosinophils. J. Immunol. Meth. 1994; 175; 23-36.
42. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol. Rev. 1999; 51; 213-340.
43. Nishikawa K, Morii T, Ako H, Hamada K, Saito S, Narita N. In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia: CD69 as a possible activation marker for eosinophils. J. Allergy Clin. Immunol. 1992; 90; 169-174.
44. Pignatti P, Perfetti L, Galdi E et al. Increased CD69 expression on peripheral blood eosinophils after specific inhalation challenge. Allergy 2002; 57; 411-416.
45. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br. J. Haematol. 1996; 95; 2-9.